痛风患者工作生产率的病程与预测因素:NOR-Gout 纵向 2 年达标治疗研究结果
NOR-Gout 观察性研究中,近期痛风发作且血尿酸(sUA)>360 µmol/l 的患者按达标治疗策略接受降尿酸治疗并密切随访 2 年。基线 WPAI 缺勤 5.0%、出勤受损 19.1%、总体工作受损 21.4%、活动受损 32.1%,前数月改善后 1 年和 2 年保持稳定;基线合并症预测 1 年时更差的工作受损和活动受损,基线对药物担忧独立预测 1 年时更差的总体工作受损和活动受损。
要点
- 基线 WPAI:缺勤 5.0%、出勤受损 19.1%、总体工作受损 21.4%、活动受损 32.1%。
- 工作生产率和活动受损在前数月改善,1 年和 2 年保持稳定。
- 基线合并症预测 1 年时更差的工作受损和活动受损,基线药物担忧独立预测 1 年时更差的总体工作受损和活动受损。
核心结论
- 在按 sUA 目标强化治疗的痛风患者中,工作生产率和活动受损基本未变,1 年时由合并症和患者对药物的担忧预测。
研究设计与样本
- NOR-Gout 观察性研究,纳入近期痛风发作且 sUA>360 µmol/l 的患者,按达标治疗策略升级降尿酸治疗并密切随访 2 年,使用 WPAI 问卷评估工作生产率和活动受损。
主要发现
- 基线平均年龄 56.4 岁,95% 为男性。
- 基线 WPAI 评分为缺勤 5.0%、出勤受损 19.1%、总体工作受损 21.4%、活动受损 32.1%。
- 工作生产率和活动受损在前数月改善,1 年和 2 年保持稳定。
- 基线合并症与基线 WPAI 评分无横断面关联,但预测 1 年时更差的工作受损和活动受损。
- 基线药物担忧量表独立预测 1 年时更差的总体工作受损和更差的活动受损。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: In patients with gout there is a lack of longitudinal studies on the course of work productivity. We explored longitudinal changes in and predictors of work productivity over 2 years. METHODS: Patients in the NOR-Gout observational study with a recent gout flare and serum urate (sUA) >360 µmol/l attended tight-control visits during escalating urate lowering therapy according to a treat-to-target strategy. From the Work Productivity and Activity Impairment (WPAI) questionnaire, scores for work productivity and activity impairment were assessed over 2 years together with the Beliefs about Medicines Questionnaire and a variety of demographic and clinical variables. RESULTS: At baseline patients had a mean age of 56.4 years and 95% were males. WPAI scores at baseline were 5.0% work missed (absenteeism), 19.1% work impairment (presenteeism), 21.4% overall work impairment and 32.1% activity impairment. Work productivity and activity impairment improved during the first months, and remained stable at 1 and 2 years. Comorbidities were not cross-sectionally associated with WPAI scores at baseline, but predicted worse work impairment and activity impairment at year 1. The Beliefs about Medicines Questionnaire subscale with concerns about medicines at baseline independently predicted worse overall work impairment and worse activity impairment at year 1. CONCLUSIONS: In patients with gout who were intensively treated to the sUA target, work productivity and activity impairment were largely unchanged and at 1 year predicted by comorbidities and patient concerns about medication.
引用
- Uhlig T, Karoliussen LF, Sexton J, et al. Course and predictors of work productivity in gout - results from the NOR-Gout longitudinal 2-year treat-to-target study. Rheumatology (Oxford). 2023. PMID: 36943375. doi:10.1093/rheumatology/kead124
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。